AI evidence synthesis, built for medicine. For those who need to know when the evidence moves.
| Claim | Verdict | Movement | Score |
|---|---|---|---|
| Efficacy | |||
UPA 30mg achieves superior EASI-75 vs placebo in moderate-to-severe AD |
Definitive | — Stable | |
IGA 0/1 clear or almost-clear skin achieved at week 16 |
Definitive | — Stable | |
Rapid itch relief within 2 weeks is superior to dupilumab |
Likely | ↑ Strengthening | |
Sustained EASI-75 response maintained at week 52 |
Likely | — Stable | |
| Comparative Efficacy | |||
UPA 30mg achieves deep response superior to dupilumab at week 16 |
Likely | ↑ Strengthening | |
EASI-75 response rate is non-inferior to tralokinumab at week 16 |
Likely | — Stable | |
Head-to-head superiority over lebrikizumab on itch NRS at week 12 |
Uncertain | — Stable | |
| Safety | |||
Serious infection rate is not elevated vs dupilumab over 52 weeks |
Definitive | ↑ Strengthening | |
Acne incidence is higher with UPA 30mg vs dupilumab in adolescents |
Likely | — Stable | |
| Class-level Safety | |||
Long-term cardiovascular risk is not elevated vs dupilumab in AD patients |
Uncertain | — Stable | |
Malignancy incidence is not elevated above background in the AD indication |
Doubtful | ↓ Weakening | |
Four AI agents working in sequence — retrieval, analysis, adversarial challenge, and calibrated verdict. Every score is traceable back to a real DOI.
ChatGPT and Claude are built to provide fluent answers. Scrutinise is built to challenge the evidence and be wrong less often where it matters most.
Pharma and biotech organisations have different functions requiring different depths of evidence access. Scrutinise is structured around three tiers that match the way decisions are actually made.